Literature DB >> 8195318

Anti-tetanus toxoid antibody production after mismatched T cell-depleted bone marrow transplantation.

M Benkerrou1, D W Wara, M Elder, Y Dror, A Merino, B W Colombe, M Garovoy, M J Cowan.   

Abstract

We explored B-cell function after tetanus toxoid (TT) immunization in 12 children with severe combined immunodeficiency disease or leukemia who were long-term survivors of an HLA-matched sibling or haplocompatible T cell-depleted parental bone marrow transplant (BMT), 10 of their healthy donors, and 13 normal controls. Specific in vivo and in vitro anti-TT antibody (Ab) production were measured by ELISA. We studied donors' and recipients' peripheral blood mononuclear cells (PBMC) and mixed E- (non-T cells) and E+ cells (T cells) spontaneously and after stimulation by TT in the absence or presence of interleukin-2 (IL-2), IL-4, and IL-6. Five of the 12 patients and all donors and controls responded with in vivo anti-TT Ab. In vitro anti-TT Ab production correlated with the in vivo response. All seven of the nonresponders were either fully engrafted or mixed chimeras (donor T cells but autologous B cells and monocytes). We could not identify a T-cell defect in four of the five nonresponders who were tested. In contrast, E- cells from three of three responders cooperated with fresh donor E+ cells even when they shared only one HLA haplotype. In three of seven nonresponders, in vitro anti-TT Ab production was restored after the addition of IL-4 or IL-6 but not IL-2. Our results suggest that the humoral immunodeficiency that exists post mismatched T cell-depleted BMT is either a B-cell, a monocyte, or a B-cell/T-cell cooperation defect which, in some patients, may be correctible with the addition of a cytokine. Also, it is not necessary to engraft donor B cells to achieve normal antibody responses and the ability to respond does not appear to correlate with pretransplant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195318     DOI: 10.1007/bf01541342

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  42 in total

Review 1.  Acute lymphoblastic leukemia: recent advances in biology and therapy.

Authors:  R Champlin; R P Gale
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

2.  Molecular signals in B cell activation. II. IL-2-mediated signals are required in late G1 for transition to S phase after ionomycin and PMA treatment.

Authors:  A Lagoo; C K Tseng; S Sell
Journal:  Cell Immunol       Date:  1990-05       Impact factor: 4.868

3.  HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease.

Authors:  R J O'Reilly; C Keever; N A Kernan; J Brochstein; N Collins; N Flomenberg; J Laver; D Emanuel; B Dupont; I Cunningham
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

Review 4.  Cell-cell interactions in the antibody response.

Authors:  A L DeFranco
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

5.  The induction and suppression of in vitro IgG anti-tetanus toxoid antibody synthesis by human lymphocytes stimulated with tetanus toxoid in the absence of in vivo booster immunizations.

Authors:  L G Lum; N J Culbertson
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

6.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Authors:  R H Buckley; S E Schiff; H A Sampson; R I Schiff; M L Markert; A P Knutsen; M S Hershfield; A T Huang; G H Mickey; F E Ward
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

7.  Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation.

Authors:  Y Dror; R Gallagher; D W Wara; B W Colombe; A Merino; M Benkerrou; M J Cowan
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

8.  Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans.

Authors:  H Kodo; R P Gale; A Saxon
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

9.  Antigen-specific antibody responses of lymphocytes to tetanus toxoid after human marrow transplantation.

Authors:  S Shiobara; L G Lum; R P Witherspoon; R Storb
Journal:  Transplantation       Date:  1986-05       Impact factor: 4.939

10.  The regulatory roles of T4 and T8 subsets in tetanus toxoid-induced in vitro immunoglobulin production.

Authors:  N Orcutt-Thordarson; L G Lum
Journal:  Cell Immunol       Date:  1983-11       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.